Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.57 |
| ▸ | RBP4 | P02753 | 1/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | LCAT | P04180 | 1/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL895533 | 0.88 | KDM4E (0.60) | ADRB1RBP4CHRM4PKMSLC6A7 | |
| SCHEMBL13485751 | 0.85 | CHRM4 (0.59) | ADRB1RBP4CHRM4PKMSLC6A7 | |
| SCHEMBL5463427 | 0.82 | ADRB1 (0.64) | ADRB1RBP4CHRM4PKMSLC6A7 | |
| SCHEMBL8354208 | 0.80 | ADRB1 (0.78) | ADRB1RBP4PKMSLC6A7CA12 | |
| SCHEMBL2328007 | 0.80 | ADRB1 (0.54) | ADRB1RBP4CHRM4PKMSLC6A7 | |
| SCHEMBL1994796 | 0.79 | ADRB1 (0.64) | ADRB1RBP4CHRM4PKMSLC6A7 | |
| SCHEMBL14923154 | 0.79 | ADRB1 (0.64) | ADRB1RBP4PKMSLC6A7LCAT | |
| SCHEMBL4765937 | 0.79 | CCR2 (0.54) | ADRB1RBP4CHRM4PKMSLC6A7 | |
| SCHEMBL19658658 | 0.79 | ACACB (0.54) | ADRB1RBP4CHRM4PKMSLC6A7 | |
| SCHEMBL19658740 | 0.79 | ADRB1 (0.53) | ADRB1RBP4CHRM4PKMSLC6A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| WO-2012135669-A1 | NITROGEN RING CONTAINING COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | WEINGARTEN M DAVID (US) | 2012-10-04 | — | — | WO | disclosed |
| US-7872006-B2 | Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| US-20090048256-A1 | Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20080275035-A1 | Nitroimidazole Compounds | JIRICEK JAN | 2008-11-06 | — | — | US | disclosed |
| EP-1984369-A2 | NITROIMIDAZOLE COMPOUNDS | Novartis AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| EP-1951678-A1 | PYRAZOLE COMPOUNDS HAVING CANNABINOID RECEPTOR (CB1) ANTAGONIZING ACTIVITY | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20080146458-A1 | PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146458-A1 | PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2008-06-19 | — | — | US | disclosed |
| US-20070265451-A1 | Process for the preparation of oxazolidinones and method of use thereof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070265451-A1 | Process for the preparation of oxazolidinones and method of use thereof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2007-11-15 | — | — | US | disclosed |
| WO-2007075872-A2 | NITROIMIDAZOLE COMPOUNDS | NOVARTIS AG (CH) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007046550-A1 | PYRAZOLE COMPOUNDS HAVING CANNABINOID RECEPTOR (CB1) ANTAGONIZING ACTIVITY | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-04-26 | — | — | WO | disclosed |
| WO-2006083266-A1 | INHIBITORS OF BACTERIAL TYPE III PROTEIN SECRETION SYSTEMS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-10 | — | — | WO | disclosed |
| US-20050272784-A1 | Inhibitors of bacterial Type III protein secretion systems | LI XIAOBING | 2005-12-08 | — | — | US | disclosed |
| WO-2005113522-A1 | AZOLE CARBOXAMIDE INHIBITORS OF BACTERIAL TYPE III PROTEIN SECRETION SYSTEMS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-12-01 | — | — | WO | disclosed |
| US-20050250819-A1 | Inhibitors of bacterial type III protein secretion systems | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265451-A1 | Process for the preparation of oxazolidinones and method of use thereof | OXA1L, OTC, ODC1 | ADRB1 3915/4885RBP4 3469/4885CHRM4 2848/4885 |
| US-20050272784-A1 | Inhibitors of bacterial Type III protein secretion systems | GBA3, PSMB3, SEC61B | ADRB1 4294/4885RBP4 3768/4885CHRM4 4789/4885 |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | ADRB1 395/4885RBP4 3977/4885CHRM4 4734/4885 |
| US-20090048256-A1 | Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity | CNR1, CNR2, OPRD1 | ADRB1 19/4885RBP4 2836/4885CHRM4 250/4885 |
| US-20050250819-A1 | Inhibitors of bacterial type III protein secretion systems | PSMB3, GBA3, PSMG3 | ADRB1 4334/4885RBP4 3932/4885CHRM4 4786/4885 |
| US-20080146458-A1 | PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF | OXA1L, OGFOD1, CYP51A1 | ADRB1 2652/4885RBP4 3198/4885CHRM4 2302/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | ADRB1 395/4885RBP4 3977/4885CHRM4 4734/4885 |
| US-20080275035-A1 | Nitroimidazole Compounds | NQO2, NQO1, MT-ND2 | ADRB1 932/4885RBP4 4806/4885CHRM4 2666/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | ADRB1 395/4885RBP4 3977/4885CHRM4 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.